Clinical efficacy of diclofenac sodium and flunixin meglumine as adjuncts to antibacterial treatment of respiratory disease of calves

Basit Öğe Kaydı
dc.contributor.authorGuzel, M.
dc.contributor.authorKarakurum, M. C.
dc.contributor.authorDurgut, R.
dc.contributor.authorMamak, N.
dc.date.accessioned2024-09-18T20:06:10Z
dc.date.available2024-09-18T20:06:10Z
dc.date.issued2010
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractObjective To compare the efficacy of the non-steroidal antiinflammatory drugs, diclofenac sodium and flunixin meglumine as adjuncts to the antibiotic treatment of bovine respiratory disease (BRD). Procedure We randomly allocated 80 Holstein calves with BRD to three groups. All the calves received a dose of 2.5 mg/kg tulathromycin by single subcutaneous injection and two of the groups received, in addition, either 2.5 mg/kg diclofenac sodium as a single intramuscular injection (diclofenac group, n = 30) or 2.2 mg/kg flunixin meglumine as an intravenous injection on the first three consecutive days after tulathromycin administration (flunixin group, n = 30). All calves were given a clinical score prior to initial treatment (day 0) and after treatment (days 1, 2, 3, 7 and 14) by observing appetite, demeanour, rectal temperature, the rate and type of respiration, presence or absence of coughing, and nasal discharge. Results During the first 48 h, improvement of adverse signs of respiratory disease, such as pyrexia and elevated respiratory rate, and of a high clinical index score was significant in the two adjunct groups compared with the calves receiving antibiotic alone. The reduction in pyrexia was greatest in the diclofenac group. There were no statically significant differences between treatment groups with regard to eventual perceived recovery from respiratory disease in 14 days. Conclusion In this trial, a single intramuscular dose of diclofenac sodium was equally effective as three intravenous injections of flunixin meglumine given on consecutive days as adjunctive therapy for BRD.en_US
dc.identifier.doi10.1111/j.1751-0813.2010.00575.x
dc.identifier.endpage239en_US
dc.identifier.issn0005-0423
dc.identifier.issue6en_US
dc.identifier.pmid20553574en_US
dc.identifier.scopus2-s2.0-77954124663en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage236en_US
dc.identifier.urihttps://doi.org/10.1111/j.1751-0813.2010.00575.x
dc.identifier.urihttps://hdl.handle.net/20.500.12483/8339
dc.identifier.volume88en_US
dc.identifier.wosWOS:000278033400025en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWiley-Blackwellen_US
dc.relation.ispartofAustralian Veterinary Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectbovine respiratory diseaseen_US
dc.subjectcalvesen_US
dc.subjectdiclofenac sodiumen_US
dc.subjectflunixin meglumineen_US
dc.subjecttulathromycinen_US
dc.titleClinical efficacy of diclofenac sodium and flunixin meglumine as adjuncts to antibacterial treatment of respiratory disease of calvesen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
Tam Metin / Full text
Boyut:
236.31 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu